Kenvue Inc. $KVUE Shares Bought by AXQ Capital LP

AXQ Capital LP raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 418.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,934 shares of the company’s stock after purchasing an additional 45,154 shares during the quarter. AXQ Capital LP’s holdings in Kenvue were worth $1,171,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Truvestments Capital LLC acquired a new position in shares of Kenvue in the 1st quarter valued at $37,000. Trust Co. of Vermont grew its stake in Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after purchasing an additional 1,150 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after purchasing an additional 1,287 shares during the period. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Kenvue by 120.6% in the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock valued at $41,000 after purchasing an additional 929 shares during the period. Finally, Ransom Advisory Ltd purchased a new position in shares of Kenvue in the first quarter worth about $56,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 3.0%

Kenvue stock opened at $16.63 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The stock has a market capitalization of $31.86 billion, a PE ratio of 22.17, a price-to-earnings-growth ratio of 2.24 and a beta of 0.71. The business has a 50 day simple moving average of $16.17 and a 200-day simple moving average of $19.82. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 5.0%. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KVUE. Johnson Rice reiterated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. JPMorgan Chase & Co. dropped their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Evercore ISI set a $18.00 price objective on shares of Kenvue in a research note on Tuesday, October 28th. Finally, Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $22.50 to $22.00 in a report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.